Since the initial 25 patients, the treatment area has been broadened and the results, according to Prof Stricker, are much improved compared to the original 76%. In addition, the improved selection of patients for this treatment has also decreased the likelihood of further treatment.
Prof Stricker feels that this treatment is a major advance in that it offers a reliable way of ablating cancers in the prostate, particularly if they are focal and treated well and appropriately selected. The initial results, which are now published and were subject to a recent press release from St Vincent's Clinic, show outstanding side effect profile with no impotence or incontinence in all the patients treated and a high rate of eradication.
